- Home
- NGNE
NGNE
Neurogene Inc.
as 11-21-2025 3:38pm EST
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 426.6M | IPO Year: | N/A |
| Target Price: | $38.50 | AVG Volume (30 days): | 291.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.88 - $37.27 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Neurogene Inc. News
NGNE Breaking Stock News: Dive into NGNE Ticker-Specific Updates for Smart Investing
Associated Press Finance
8 days ago
Neurogene: Q3 Earnings Snapshot
Business Wire
8 days ago
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
Business Wire
9 days ago
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
Business Wire
16 days ago
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Business Wire
16 days ago
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
Business Wire
a month ago
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
Business Wire
3 months ago
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare NGNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NGNE Neurogene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.